5 Most Promising Long-Term Stocks According to Analysts

3. Valneva SE (NASDAQ:VALN)

Average Analyst Share Price Target Percentage Upside: 96.71%

Average Share Price Target: $20.32

Valneva SE (NASDAQ:VALN) is a French biotechnology company developing treatments for diarrhea, Lyme disease, and other ailments. Its Lyme disease trial is moving fast these days, and in partnership with Pfizer, Valneva SE (NASDAQ:VALN) finished phase three enrollments in December 2023.

During 2023’s September quarter, just one out of the 910 hedge funds part of Insider Monkey’s database were Valneva SE (NASDAQ:VALN)’s shareholders. This lone investor was Benjamin A. Smith’s Laurion Capital Management as it owns $295,000 worth of shares.

Follow Valneva Se